Member Info for Malachi

Well well, a new application for Parsortix; we're made now.

IMHO share will surely go nowhere, perhaps for rest of 2019, until FDA approval. It might creep up in anticipation early 2020. Meanwhile this is yet another positive study showing the TOTAL superiority of analysis of CTS by Parsortix over looking for cRNA fragments, a veritable rusty needle in a large haystack. Keep the faith!

"De Nora has commenced work on the scaling up of the electrode chemistry at its German manufacturing facility to ensure consistency, replicability and quality assurance in advance of large-scale electrode orders" It is one thing to produce a one-off electrode for testing , and quite another to mass produce it to the same performance spec. This, as usual, is somewhere in the future.

Stokey, good point

"....we have demonstrated our technology to Peel over an extensive due diligence period and we have met the Peel criteria, not only technically but, more importantly, commercially". And yet the SP response to a wholly positive RNS is muted. Odd.
But we still have PHE deniers amongst us- just like dear old Pomander the much loved prophet of doom from a year or 2 back. I think they, and Pomander, will be proved wrong.

Stanman "the first company to have an FDA-cleared platform for harvesting cancer cells from patient’s blood for analysis.” This was the bottom line of the article, but I also understood that the present FDA application will apply to ca. breast only. If this is the case I would expect that further applications for other malignancies would have a much easier/quicker approval. But as you mention there is a distinction between the use of the kit for isolating the malignant cells, and the subsequent downstream analyses, which may not all be the same in terms of sensitivity/ specificity, and may require approval on a case by case basis.

I wonder whether the Rotec deal towards charging points is a step in the wrong direction? I hope not all eggs are in this particular basket. I have an impression that battery powered electric cars will be a passing phase on the way to hydrogen powered vehicles with fuel cells powered by hydrogen/oxygen. AFC should be aiming to get into this market.

Is it stated anywhere for how long d2p is active? The brochure mentioned by Ox042 mentions 'long periods' While this is not important for disposables, other areas such as plastic surfaces it probably matters as a selling point. Anyway, what a good day.

So someone in PHE reads this board. Well done Piltick! And a 10% uptick

PKOK, in what way is this an admission of failure to meet FDA submission objectives? Which is the 'hidden away' paragraph to which you refer?. Can you clarify what you mean in your second sentence, please, as it is incomprensible at present. Thanks.

There has been some discussion about AGL being taken out by a big beast , perhaps after FDA approval. My take, supported by todays RNS is that AGL wants to, and probably can remain independent. The idea of an independent lab owned by AGLextracting CTS for trials performed by others and researching better ways to culture CTS suggests to me AGL becoming a powerful player in the cancer world, rather than just a seller of a very clever simple mousetrap. It is of course possible for someone to offer a crazy price, but that price is going to go increase with every development by AGL. We will see.

This is just one of a long string of brilliant RNS, each of which flicks the SP up for a few days, and then back to square one - or nearly. The big sustained rise will surely only come when FDA approves the present submission for breast cancer, and this submission is, I understand, inextricably linked to the results of the downstream genetic analysis. What I am uncertain about is how easy will it then be for the Parsortix mousetrap to gain FDA approval to be used for other cancers, lymphomas, and, for that matter, the analysis of foetal red cells for diagnosing inherited foetal abnormalities, Downs syndrome et al, ? Does anyone on the board have an insight into FDA procedure in this?

In your second para you refer to plastics breaking down into micro-organisms. You mean small molecules, I think.

Production companies seem more interested in shock / horror revelations (in all spheres of activity), than in solutions.
They are less interested in demonstrating solutions - it is not, in their view - good TV

Yellowf1. Agreed, presentational skills are very poor and this is no help to PHE or its long suffering PIs. Someone needs to give him a few tips, including not having over-reliance on the dreaded Powerpoint.

Geovanni. The paper you cite gives a useful insight into the complexities of approval by FDA. Thank you for citing it. The Parsortix device is inextricably linked to the subsequent use of the isolated cancer cell, both the subsequent genetic or other testing , and the intended therapeutic /treatment activity that follows. I suspect there will be no problem for the FDA with the isolation of CDCs using Parsortix, but there is potential for problems arising from the validity of the subsequent investigations performed on the cell contents, etc in determining treatment.

With great respect, Morgank, it it necessary to paste the RNS with the share chat when it is easily seen with a couple of clicks with all the other RNS's? Sorry to be picky.

Ted B
Write what off as nonsense?

Excellent news regardless of the source of the NH3, and I am therefore surprised at the muted response of the sp.

Oxygen is essential to the process of oxobiodegradation.The rate of degradation is presumably determined by the pO2 in some way. So in buried material, or at the bottom of the sea, where pO2 is very low, degradation will be very slow. Think of leaves buried at the bottom of a compost heap, (or a fossilised leaf) They do not decompose. The point I am making is that there will always be some circumstances in which oxobiodegradation does not work as well as where there is plenty of oxygen, and these examples can be used by detractors, competitors, or mad professors etc,.